Until recently, the number of children treated with statin was unknown. Therefore, Karianne Svendsen (University of Oslo, Norway) and colleagues aimed to describe the number of statin users younger than 19 years in Sweden, Denmark, and Norway [1]. The authors assumed that the number of children who would be using statins is equivalent to a positive familial hypercholesterolemia diagnosis in these three Nordic countries. As the estimated frequency of familial hypercholesterolemia is 1:250, the number of expected children suffering from the disease per year could be calculated. They then calculated the percentage of all children with familial hypercholesterolemia who were treated according to the national registries, which hold information on all prescription drugs being handed out. The researchers also calculated any changes between 2006 and 2016.
Results showed that in 2016, a total of 1,086 Scandinavian children aged between 5-19 years (51% girls and 48% boys) used statins. Norwegian children with familial hypercholesterolemia aged 10-19 years used statins more frequently than children in Denmark and Sweden. However, an increase from 2% to 4% was seen in the use of statins in children aged 5-19 years between 2006 and 2016 in Sweden (n=109) and in Denmark (n=136). In Norway, statin use increased from about 5% to 10% (n=340). Thus, during a 10-year period, a modest increase in statin users aged 5-19 years in the Scandinavian countries was seen. It was also highlighted that implementing the current statin recommendation will take many years.
1. Svendsen K, et al. Statin treatment in children with familial hypercholesterolemia in Scandinavia. FP Number P1224. ESC Congress 2019, 31 Aug-4 Sept, Paris, France.
Posted on
Previous Article
« Early use ICD after PCI shows beneficial effect on survival in patients at high risk of death after STEMI Next Article
Salt substitution programme successful in lowering blood pressure »
« Early use ICD after PCI shows beneficial effect on survival in patients at high risk of death after STEMI Next Article
Salt substitution programme successful in lowering blood pressure »
Related Articles
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com